Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry Journal Article
| Authors: | Bartsch, R.; Frings, S.; Marty, M.; Awada, A.; Berghoff, A. S.; Conte, P.; Dickin, S.; Enzmann, H.; Gnant, M.; Hasmann, M.; Hendriks, H. R.; Llombart, A.; Massacesi, C.; Von Minckwitz, G.; Penault-Llorca, F.; Scaltriti, M.; Yarden, Y.; Zwierzina, H.; Zielinski, C. C. |
| Article Title: | Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry |
| Abstract: | Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
| Keywords: | vasculotropin; cancer chemotherapy; protein expression; treatment outcome; overall survival; drug tolerability; bevacizumab; placebo; cancer combination chemotherapy; dose response; drug dose comparison; hypertension; monotherapy; unspecified side effect; capecitabine; paclitaxel; cancer adjuvant therapy; drug megadose; unindexed drug; vasculotropin receptor; progression free survival; breast cancer; bleeding; epidermal growth factor receptor 2; antineoplastic activity; brca1 protein; phosphatidylinositol 3 kinase; cancer research; cancer mortality; cancer resistance; docetaxel; exemestane; loading drug dose; drug cost; genome analysis; tumor suppressor gene; survival time; drug research; kidney injury; thrombosis; tamoxifen; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; clinical decision making; letrozole; pharmacogenetics; intestine perforation; taxane derivative; estrogen receptor; drug control; trastuzumab; anastrozole; navelbine; anthracycline; breast metastasis; wound healing impairment; antiangiogenic activity; everolimus; proteinuria; lapatinib; fulvestrant; pertuzumab; drug industry; heart injury; molecularly targeted therapy; triple negative breast cancer; trastuzumab emtansine; tp53 gene; cancer prognosis; her2 gene; dna end joining repair; dovitinib; buparlisib; basal like breast cancer; human; priority journal; article; biological subtypes; her2-positive disease; luminal disease; triple-negative disease; dactolisib; palbociclib; luminal breast cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | 4 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-01-01 |
| Start Page: | 773 |
| End Page: | 780 |
| Language: | English |
| DOI: | 10.1093/annonc/mdt531 |
| PROVIDER: | scopus |
| PUBMED: | 24351401 |
| DOI/URL: | |
| Notes: | Export Date: 1 May 2014 -- Art. No.: mdt531 -- CODEN: ANONE -- Source: Scopus |
